And this polymorphism was associated not only with higher portal vein tumor risk and tumor dedifferentiation, but also with increasing the mutation risk of TP53 gene and modifying the targetted ADAMTS4 gene expression [46]. This evidence concerns the gene TP53 and neoplasm.